Xenotransplantation: Advancing Medical Innovation Through Cross-Species Transplantation

Xenotransplantation, the transplantation of organs or tissues from one species to another, is at the forefront of medical innovation. It offers a promising solution to the critical shortage of organs for transplantation and presents new avenues for treating a variety of diseases. As we consolidate key findings from recent studies, a comprehensive overview of xenotransplantation and its associated cellular therapies emerges, revealing the current state and future prospects of this groundbreaking field.

The use of porcine organs for human transplantation is particularly promising. Genetic engineering has shown significant potential in reducing the immunological barriers that have historically posed a challenge. While Arabi et al. ¹ delve into the intricacies of hyperacute rejection (HAR) and acute cellular rejection, Cao et al. ² introduce an innovative approach to immunomodulation. This approach enhances the suppressive functions of human regulatory T cells, known as xeno-Tregs, which are pivotal in preventing xenograft rejection.

In the realm of xenografting, O’Neill et al. ³ have optimized methods to generate human skeletal muscle in mice. This advancement is not only a significant technical achievement but also a crucial step forward in the study of muscle pathology. Similarly, Harland et al. ⁴ explore the xenogenic application of human placenta-derived mesenchymal stromal cells in pigs. Their findings underscore the potential of these cells for regenerative medicine, with the added benefit of evading a robust immune response.

Addressing the critical issues of immunological rejection and the risk of viral infections is essential in xenotransplantation. Zhou et al. ⁵ provide an in-depth review of the viral infections associated with the procedure, highlighting the necessity for sensitive diagnostics and effective antiviral therapies. Meanwhile, Suh et al. ⁶ reveal that additional genetic modifications do not always prevent renal damage in pig-to-nonhuman primate transplants, underscoring the need for improved immune suppression strategies.

As we navigate the complex landscape of xenotransplantation, ethical, legal, and social considerations come to the forefront. Brown et al. ⁷ engage in a critical examination of these aspects, particularly in the context of human-animal chimera research. They advocate for a proactive regulatory approach that is informed by scientific evidence and public engagement, emphasizing the importance of balancing innovation with responsibility.

In the field of neurological treatment, cellular therapies are making significant strides. Strell et al. ⁸ explore the use of blastocyst complementation for generating exogenic neurons to treat Alzheimer’s disease, emphasizing the importance of understanding the developmental biology of affected neuronal cell types. Shetty et al., ⁹ on the other hand, enhance organ development through interspecies chimerism, addressing the shortage of transplantable organs by identifying the best-matched developmental stages across species.

Ma et al. ¹⁰ investigate the immunosuppressive effects of leflunomide in a rat-to-mouse cardiac xenotransplantation model, providing evidence for its potential use in xenotransplantation. Yoshida et al. ¹¹ present a therapeutic approach using human amniotic mesenchymal stem cells (hAMSCs) for cerebral infarction treatment, demonstrating their ability to ameliorate neurological deficits. Furthermore, Var et al. ¹² discuss the role of microglia in treating central nervous system (CNS) injuries and neurological diseases, emphasizing the potential of transplanting exogenic microglia for protection against inflammation and neuronal damage.

In vivo models are proving to be invaluable in advancing our understanding and therapeutic strategies. Huang et al. ¹³ establish a zebrafish xenograft model for nasopharyngeal carcinoma (NPC), offering a unique system for investigating tumorigenesis and NPC progression. The ability to visualize tumor cell behavior in real time is particularly noteworthy for understanding disease mechanisms and testing therapeutic strategies. In the realm of stem cell therapies, Mizuno et al. ¹⁴ present a promising method for laryngeal cartilage regeneration using mesenchymal stem cells derived from human-induced pluripotent stem cells (hiPSCs). This approach demonstrates the potential for tissue engineering solutions to reconstructive surgery challenges, offering an alternative to autologous or allogeneic transplants.

Li et al. ¹⁵ explore the protective effects of reduced glutathione and ulinastatin on xeno-transplanted human ovarian tissue, addressing a critical issue in fertility preservation. Their findings suggest that these agents can decrease follicle depletion post-transplantation by inhibiting ischemia reperfusion-induced antiangiogenesis, oxidative stress, and inflammation.

As we stand on the precipice of significant medical breakthroughs, the collective research underscores the rapid progress and diverse approaches in xenotransplantation and cellular therapies. From overcoming immunological hurdles to addressing ethical considerations, each study contributes to our understanding of the biological mechanisms and the complex interplay of factors that must be considered. It is imperative that the scientific community, policymakers, and the public engage in a constructive dialogue to ensure that these transformative therapies are developed and applied with the utmost consideration for safety, equity, and societal impact.

For further insights into xenotransplantation and cellular therapies, readers are encouraged to explore the collection at Xenograft Models and Xenogeneic Cells: Cell Transplantation: Sage Journals (https://journals.sagepub.com/topic/collections-cll/cll-1-xenograft_models_and_xenogeneic_cells?journalCode=cll).